No Data
No Data
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
TD Cowen analyst Yaron Werber maintains $Stoke Therapeutics(STOK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 60.9% and a total average return of 16.1% over
Stoke Therapeutics (STOK) Gets a Buy From TD Cowen
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
BTIG analyst Thomas Shrader maintains $Stoke Therapeutics(STOK.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 39.1% and a
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright analyst Andrew Fein maintains $Stoke Therapeutics(STOK.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 44.7%
HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
Buy Recommendation for Stoke Therapeutics Backed by STK-001's Promising Therapeutic Impact on Dravet Syndrome